[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018003649A - Metodos e intermedios para la preparacion de derivados de acido biliar. - Google Patents

Metodos e intermedios para la preparacion de derivados de acido biliar.

Info

Publication number
MX2018003649A
MX2018003649A MX2018003649A MX2018003649A MX2018003649A MX 2018003649 A MX2018003649 A MX 2018003649A MX 2018003649 A MX2018003649 A MX 2018003649A MX 2018003649 A MX2018003649 A MX 2018003649A MX 2018003649 A MX2018003649 A MX 2018003649A
Authority
MX
Mexico
Prior art keywords
methods
acid derivatives
bile acid
intermediates
preparation
Prior art date
Application number
MX2018003649A
Other languages
English (en)
Inventor
Schaab Kevin
E Whitley Paul
Chavez Flavio
R Iorga Kayla
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2018003649A publication Critical patent/MX2018003649A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invenci6n se refiere a métodos e intermedios novedosos útiles en la preparación de un compuesto o una sal farmacéuticamente aceptable del mismo. Un objetivo de la presente invención es proporcionar métodos para preparar derivados de ácidos biliares e intermedios novedosos. Un use de los métodos e intermedios descritos se refiere a la síntesis de derivados de ácidos biliares que activan tanto FXR como TGR5.
MX2018003649A 2015-09-24 2016-09-23 Metodos e intermedios para la preparacion de derivados de acido biliar. MX2018003649A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222943P 2015-09-24 2015-09-24
PCT/US2016/053483 WO2017053826A1 (en) 2015-09-24 2016-09-23 Methods and intermediates for the preparation bile acid derivatives

Publications (1)

Publication Number Publication Date
MX2018003649A true MX2018003649A (es) 2018-05-11

Family

ID=58387485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003649A MX2018003649A (es) 2015-09-24 2016-09-23 Metodos e intermedios para la preparacion de derivados de acido biliar.

Country Status (13)

Country Link
US (1) US11072631B2 (es)
EP (1) EP3353189A4 (es)
JP (1) JP2018528230A (es)
KR (1) KR20180052756A (es)
CN (1) CN108350020A (es)
AR (1) AR106141A1 (es)
AU (1) AU2016325619A1 (es)
CA (1) CA2999302A1 (es)
HK (1) HK1254057A1 (es)
IL (1) IL258113A (es)
MX (1) MX2018003649A (es)
TW (1) TW201718622A (es)
WO (1) WO2017053826A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703717SA (en) 2014-11-06 2017-06-29 Enanta Pharm Inc Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
JP2017535570A (ja) 2014-11-26 2017-11-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
WO2016130809A1 (en) 2015-02-11 2016-08-18 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
SI3277286T1 (sl) 2015-03-31 2021-09-30 Enanta Pharmaceuticals, Inc. Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2018064441A1 (en) * 2016-09-30 2018-04-05 Intercept Pharmaceuticals, Inc Crystalline forms of a bile acid derivative
EP3548038B1 (en) 2016-11-29 2022-04-13 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
AU2018249950B2 (en) 2017-04-07 2023-09-21 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
US11059854B2 (en) * 2017-07-26 2021-07-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing steroid derivative FXR agonist
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) * 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
PL2040713T3 (pl) * 2006-06-27 2014-11-28 Intercept Pharmaceuticals Inc Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
EP2698375B1 (en) * 2008-11-19 2018-02-21 Intercept Pharmaceuticals, Inc. TGR5 modulators and method of use thereof
NZ703072A (en) 2012-06-19 2016-06-24 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
PT2912013T (pt) 2012-10-26 2018-01-03 Intercept Pharmaceuticals Inc Processo de preparação de derivados de ácidos biliares
RU2693382C2 (ru) * 2012-11-28 2019-07-02 Интерсепт Фармасьютикалз, Инк. Лечение заболевания дыхательной системы
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
LT3149019T (lt) * 2014-05-29 2020-02-25 Bar Pharmaceuticals S.R.L. Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai
SG11201706347SA (en) 2015-02-06 2017-09-28 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
CN108137643A (zh) * 2015-08-07 2018-06-08 英特塞普特医药品公司 制备胆汁酸及其衍生物的方法
CN108348543A (zh) 2015-09-21 2018-07-31 英特塞普特医药品公司 促进肝再生的方法

Also Published As

Publication number Publication date
IL258113A (en) 2018-05-31
AR106141A1 (es) 2017-12-13
EP3353189A4 (en) 2019-06-19
AU2016325619A1 (en) 2018-04-12
TW201718622A (zh) 2017-06-01
US11072631B2 (en) 2021-07-27
KR20180052756A (ko) 2018-05-18
CN108350020A (zh) 2018-07-31
WO2017053826A1 (en) 2017-03-30
HK1254057A1 (zh) 2019-07-12
JP2018528230A (ja) 2018-09-27
EP3353189A1 (en) 2018-08-01
US20200239515A1 (en) 2020-07-30
CA2999302A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2018003649A (es) Metodos e intermedios para la preparacion de derivados de acido biliar.
IL304455A (en) Methods and intermediates for the preparation of bile acid derivatives
MX2022005610A (es) Pirimidina-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
MX361653B (es) Procedimiento para la preparación de derivados del ácido biliar.
WO2012173682A3 (en) Compounds and methods for the treatment of isocitrate dehydrognase related diseases
IN2014CH00247A (es)
JO3722B1 (ar) مثبطات 6-(5- هيدروكسي-1h- بيرازول-1- يل) و مشتقات نيكوتيناميد واستخدامها كمثبطات
PH12016501941B1 (en) Use of heterocyclic compounds for controlling nematodes
IN2013MU02828A (es)
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
PH12017500595B1 (en) Aldosterone synthase inhibitors
MX2020000873A (es) Derivados de ácidos biliares marcados isotópicamente.
MX2019003684A (es) Formas cristalinas de un derivado de acido biliar.
IN2014DN08443A (es)
IN2013MU04056A (es)
PH12017500492A1 (en) Crystalline bace inhibitors
IN2015CH02092A (es)
IN2013MU02813A (es)
IN2013MU02612A (es)
IN2014MU00070A (es)
IN2014MU00071A (es)